Related Experiment Videos
Latent antigen vaccination in a model gammaherpesvirus infection
E J Usherwood1, K A Ward, M A Blackman
1The Trudeau Institute, Saranac Lake, New York 12983, USA.
Abstract:
Vaccines that can reduce the load of latent gammaherpesvirus infections are eagerly sought. One attractive strategy is vaccination against latency-associated proteins, which may increase the efficiency with which T cells recognize and eliminate latently infected cells. However, due to the lack of tractable animal model systems, the effect of latent-antigen vaccination on gammaherpesvirus latency is not known. Here we use the murine gammaherpesvirus model to investigate the impact of vaccination with the latency-associated M2 antigen. As expected, vaccination had no effect on the acute lung infection. However, there was a significant reduction in the load of latently infected cells in the initial stages of the latent infection, when M2 is expressed. These data show for the first time that latent-antigen vaccination can reduce the level of latency in vivo and suggest that vaccination strategies involving other latent antigens may ultimately be successfully used to reduce the long-term latent infection.
Insights
Vaccinating against latent gammaherpesvirus (GHV) M2 antigen reduced infected cells in mice. This study demonstrates latent-antigen vaccination can decrease viral latency in vivo, offering new strategies for infection control.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Gammaherpesvirus (GHV) infections establish lifelong latency, posing significant health challenges.
- Vaccination strategies targeting latency-associated proteins are proposed to enhance T cell-mediated clearance of infected cells.
- The in vivo efficacy of latent-antigen vaccination against GHV latency remains largely unexplored due to limited animal models.
Purpose of the Study:
- To investigate the impact of vaccination with the latency-associated M2 antigen on murine gammaherpesvirus (MHV) infection.
- To determine if targeting latent antigens can reduce the viral load during the latent phase of infection.
Main Methods:
- Utilized the murine gammaherpesvirus (MHV) model system.
- Administered vaccination against the latency-associated M2 antigen.
- Assessed viral load during acute and latent infection stages.
Main Results:
- Vaccination showed no impact on the acute phase of MHV lung infection.
- A significant reduction in the load of latently infected cells was observed during the early stages of latency, coinciding with M2 expression.
- These findings provide the first in vivo evidence for the efficacy of latent-antigen vaccination in reducing viral latency.
Conclusions:
- Latent-antigen vaccination, specifically targeting the M2 antigen, can effectively reduce the burden of gammaherpesvirus latency in vivo.
- This study supports the potential of developing novel vaccination strategies utilizing other latent antigens to mitigate long-term gammaherpesvirus infections.
- Further research into latent-antigen vaccination holds promise for controlling persistent viral infections.